Drug Development Pipeline
SPI-1005 is an oral form of the drug ebselen. Ebselen is a molecule designed to mimic the function of a key enzyme found in the inner ear, glutathione peroxidase (GPx). Regular use of aminoglycoside antibiotics can cause damaging side effects in the inner ear. By mimicking the function of GPx, SPI-1005 may protect the inner ear from damage.
A Phase 2 study to test the safety and tolerability of SPI-1005 in people with CF is currently underway.
This program is sponsored by Sound Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
Recent SPI-1005 Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More